- Home
- OI vs PVLA Comparison
OI vs PVLA Comparison
Compare OI & PVLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OI | PVLA |
|---|---|---|
| Founded | 1903 | 2015 |
| Country | United States | United States |
| Employees | N/A | 14 |
| Industry | Containers/Packaging | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.6B |
| IPO Year | 1994 | N/A |
Fundamental Metrics
Financial Performance| Metric | OI | PVLA |
|---|---|---|
| Price | $9.13 | $130.18 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 15 |
| Target Price | $15.29 | ★ $171.87 |
| AVG Volume (30 Days) | ★ 2.3M | 160.9K |
| Earning Date | 04-28-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $6,426,000,000.00 | N/A |
| Revenue This Year | $2.77 | N/A |
| Revenue Next Year | $1.88 | $104,350.18 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $8.00 | $20.20 |
| 52 Week High | $16.91 | $151.18 |
Technical Indicators
Market Signals| Indicator | OI | PVLA |
|---|---|---|
| Relative Strength Index (RSI) | 37.52 | 55.58 |
| Support Level | $8.00 | $108.99 |
| Resistance Level | $13.46 | $135.23 |
| Average True Range (ATR) | 0.54 | 6.85 |
| MACD | -0.11 | -0.17 |
| Stochastic Oscillator | 36.12 | 59.42 |
Price Performance
Historical ComparisonAbout OI O-I Glass Inc.
O-I Glass is the manufacturer of glass containers. The Company has two reportable segments and two operating segments based on its geographic locations: Americas and Europe. Beer is the primary end market for O-I's glass bottles, which are also used for wine, soda, spirits, condiments, and food.
About PVLA Palvella Therapeutics Inc.
Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company's lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company's patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders.